- Home
- OKTA vs RPRX Comparison
OKTA vs RPRX Comparison
Compare OKTA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKTA
- RPRX
- Stock Information
- Founded
- OKTA 2009
- RPRX 1996
- Country
- OKTA United States
- RPRX United States
- Employees
- OKTA N/A
- RPRX N/A
- Industry
- OKTA Computer Software: Prepackaged Software
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- OKTA Technology
- RPRX Health Care
- Exchange
- OKTA Nasdaq
- RPRX Nasdaq
- Market Cap
- OKTA 14.6B
- RPRX 11.7B
- IPO Year
- OKTA 2017
- RPRX 2020
- Fundamental
- Price
- OKTA $78.83
- RPRX $25.79
- Analyst Decision
- OKTA Buy
- RPRX Strong Buy
- Analyst Count
- OKTA 36
- RPRX 6
- Target Price
- OKTA $104.46
- RPRX $41.67
- AVG Volume (30 Days)
- OKTA 4.3M
- RPRX 3.1M
- Earning Date
- OKTA 02-26-2025
- RPRX 02-13-2025
- Dividend Yield
- OKTA N/A
- RPRX 3.26%
- EPS Growth
- OKTA N/A
- RPRX 518.56
- EPS
- OKTA N/A
- RPRX 2.55
- Revenue
- OKTA $2,533,000,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- OKTA $17.06
- RPRX $12.21
- Revenue Next Year
- OKTA $8.08
- RPRX $11.13
- P/E Ratio
- OKTA N/A
- RPRX $10.10
- Revenue Growth
- OKTA 16.84
- RPRX N/A
- 52 Week Low
- OKTA $70.56
- RPRX $24.05
- 52 Week High
- OKTA $114.50
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- OKTA 43.61
- RPRX 52.96
- Support Level
- OKTA $80.16
- RPRX $25.18
- Resistance Level
- OKTA $84.13
- RPRX $25.68
- Average True Range (ATR)
- OKTA 2.36
- RPRX 0.47
- MACD
- OKTA -0.81
- RPRX 0.13
- Stochastic Oscillator
- OKTA 4.52
- RPRX 95.08
About OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.